Roche Appeals Negative EMEA Decision For Tarceva Pancreatic Cancer Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
EMEA has 60 days to review Tarceva on appeal; the oncologic is approved for treatment of advanced pancreatic cancer in the U.S.
You may also be interested in...
EMEA’s CHMP Reverses Stance On Roche’s Tarceva
CHMP also recommends marketing authorization for J&J’s Prezista and Orphan Europe SARL’s Cystadane.
EMEA’s CHMP Reverses Stance On Roche’s Tarceva
CHMP also recommends marketing authorization for J&J’s Prezista and Orphan Europe SARL’s Cystadane.
NICE Draft Negs Tarceva, Alimta For Treatment Of NSCLC
Neither Roche's erlotinib or Lilly's pemetrexed represent "good use of scarce" resources, NICE says in preliminary reports.